KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non Operating Income: 2009-2024

Historic Non Operating Income for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to -$200.5 million.

  • Alnylam Pharmaceuticals' Non Operating Income fell 306.24% to -$129.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$296.6 million, marking a year-over-year decrease of 123.08%. This contributed to the annual value of -$200.5 million for FY2024, which is 32.47% down from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Non Operating Income is -$200.5 million, which was down 32.47% from -$151.3 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Non Operating Income registered a high of $57.3 million during FY2020, and its lowest value of -$341.9 million during FY2022.
  • In the last 3 years, Alnylam Pharmaceuticals' Non Operating Income had a median value of -$200.5 million in 2024 and averaged -$231.3 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Non Operating Income slumped by 350.27% in 2021 and then surged by 55.74% in 2023.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Non Operating Income stood at $57.3 million in 2020, then slumped by 350.27% to -$143.5 million in 2021, then slumped by 138.29% to -$341.9 million in 2022, then skyrocketed by 55.74% to -$151.3 million in 2023, then tumbled by 32.47% to -$200.5 million in 2024.